Harmony Biosciences Statistics
Share Statistics
Harmony Biosciences has 57.42M
shares outstanding. The number of shares has increased by 0.97%
in one year.
| Shares Outstanding | 57.42M |
| Shares Change (YoY) | 0.97% |
| Shares Change (QoQ) | 0.55% |
| Owned by Institutions (%) | 92.67% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 2,649 |
| FTD / Avg. Volume | 0.35% |
Short Selling Information
The latest short interest is 3.25M, so 5.66% of the outstanding
shares have been sold short.
| Short Interest | 3.25M |
| Short % of Shares Out | 5.66% |
| Short % of Float | 12.41% |
| Short Ratio (days to cover) | 5.84 |
Valuation Ratios
The PE ratio is 13.45 and the forward
PE ratio is 8.49.
Harmony Biosciences's PEG ratio is
0.75.
| PE Ratio | 13.45 |
| Forward PE | 8.49 |
| PS Ratio | 2.74 |
| Forward PS | 1 |
| PB Ratio | 2.97 |
| P/FCF Ratio | 8.95 |
| PEG Ratio | 0.75 |
Financial Ratio HistoryEnterprise Valuation
Harmony Biosciences has an Enterprise Value (EV) of 1.68B.
| EV / Sales | 2.36 |
| EV / EBITDA | 7.21 |
| EV / EBIT | 7.66 |
| EV / FCF | 7.7 |
Financial Position
The company has a current ratio of 3.31,
with a Debt / Equity ratio of 0.27.
| Current Ratio | 3.31 |
| Quick Ratio | 3.27 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | 0.77 |
| Debt / FCF | 0.82 |
| Interest Coverage | 10.91 |
Financial Efficiency
Return on Equity is 22.07% and Return on Invested Capital is 17.22%.
| Return on Equity | 22.07% |
| Return on Assets | 14.56% |
| Return on Invested Capital | 17.22% |
| Revenue Per Employee | $2,666,917.91 |
| Profits Per Employee | $542,884.33 |
| Employee Count | 268 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 21.79 |
Taxes
| Income Tax | 46.31M |
| Effective Tax Rate | 24.14% |
Stock Price Statistics
The stock price has increased by 12.46% in the
last 52 weeks. The beta is 0.82, so Harmony Biosciences's
price volatility has been higher than the market average.
| Beta | 0.82 |
| 52-Week Price Change | 12.46% |
| 50-Day Moving Average | 31.74 |
| 200-Day Moving Average | 34.59 |
| Relative Strength Index (RSI) | 58.76 |
| Average Volume (20 Days) | 764,171 |
Income Statement
In the last 12 months, Harmony Biosciences had revenue of 714.73M
and earned 145.49M
in profits. Earnings per share was 2.56.
| Revenue | 714.73M |
| Gross Profit | 557.92M |
| Operating Income | 190.83M |
| Net Income | 145.49M |
| EBITDA | 233.41M |
| EBIT | 209.3M |
| Earnings Per Share (EPS) | 2.56 |
Full Income StatementBalance Sheet
The company has 453M in cash and 179.27M in
debt, giving a net cash position of 273.74M.
| Cash & Cash Equivalents | 453M |
| Total Debt | 179.27M |
| Net Cash | 273.74M |
| Retained Earnings | 2.22M |
| Total Assets | 1.06B |
| Working Capital | 467.57M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 219.82M
and capital expenditures -1.15M, giving a free cash flow of 218.67M.
| Operating Cash Flow | 219.82M |
| Capital Expenditures | -1.15M |
| Free Cash Flow | 218.67M |
| FCF Per Share | 3.84 |
Full Cash Flow StatementMargins
Gross margin is 78.06%, with operating and profit margins of 26.7% and 20.36%.
| Gross Margin | 78.06% |
| Operating Margin | 26.7% |
| Pretax Margin | 26.84% |
| Profit Margin | 20.36% |
| EBITDA Margin | 32.66% |
| EBIT Margin | 26.7% |
| FCF Margin | 30.59% |
